BAYRY Stock Recent News

BAYRY begins human trials for OpCT-001, an experimental cell therapy for treating primary photoreceptor diseases.

Bayer (BAYRY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ST. LOUIS--(BUSINESS WIRE)--Bayer today announced the appointment of Priyal Patel as Cluster Chief Financial Officer (CFO) for North America, effective July 1, 2025. In her new role, Patel will oversee financial strategy and operations across Bayer's North American businesses while continuing to serve as Head of Treasury for Bayer North America. She succeeds Guru Ramamurthy, who was recently appointed the new CFO for Bayer's Crop Science division. With over two decades of experience, Patel brin.

The U.S. Supreme Court asked President Donald Trump's administration on Monday for its views on Bayer's bid to sharply limit lawsuits claiming that the company's Roundup weedkiller causes cancer and potentially avert billions of dollars in damages.

Bayer said on Monday that the U.S. Supreme Court had asked the solicitor general for an opinion in the Durnell case, as the German company seeks clarity from the top U.S. court in litigation related to its weedkiller glyphosate.

Following the Bayer-Monsanto merger, litigation has resulted in a valuable settlement that, pending final approval, affirms the rights of ADR investors to

Bayer share price has bounced back this year, making it one of the best-performing companies in the German DAX Index. It has jumped to €26, up by 45% from its lowest point this year.

Prestigious International Annual Awards Program Honors Standout AI Companies & Solutions Prestigious International Annual Awards Program Honors Standout AI Companies & Solutions

BAYRY files for FDA nod to gadoquatrane, a low-dose MRI contrast agent backed by strong QUANTI study results.

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its investigational contrast agent gadoquatrane for contrast-enhanced magnetic resonance imaging of the CNS and other body regions in adults and pediatric patients including term neonates. The submitted dose is 0.04 mmol gadolinium per kilogram body weight. If approved, gadoquatrane would become the lowest dose macrocyclic GBCA available in the U.